LAM 2002;12(8):503.

KIGYÓGYÍT

Betűrendes mutató

Az összeállítás a folyóiratunkban 1991 és 2002 szeptembere között kivonatos formában megjelent tanulmányokat tartalmazza a megjelenés idejének feltüntetésével.

ACCEPT (Accupril Canadian Clinical Evaluation and Patient Teaching); 2001/7–8

ACCT (Amplodipine Cardiovascular Community Trial); 1998/7–8

ACME (Angioplasty Compared to MEdicine); 1993/5

AIMS (APSAC Intervention Mortality Study); 1992/11

AIRE (Acute Infarction Ramipril Efficacy); 1999/11

AIREX (Acute Infarction Ramipril Efficacy EXtension Study); 1999/11

AMIS (Aspirin Myocardial Infarction Study); 1993/11

ANBP (Australian National Blood Pressure trial); 1995/3

APSI (Acebutolol et Prévention Secondaire de l’Infarctus); 1996/7–8

APSIM (APSAC dans l’Infarctus du Myocarde); 1992/10

APSIS (Angina Prognosis Study In Stockholm); 1999/4

ARMS (Anistreplase Reocclusion Multicenter Study); 1995/10

ASAAC (AcetylSalicylic Acid versus AntiCoagulants); 1995/12

ASIST (Atenolol Silent Ischemia STudy); 1996/3–4

ASPECT (Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis); 1996/5–6

ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events); 2000/3

ATEST(ATEnolol and Streptokinase Trial); 1997/10

ATIME (Quinapril Titration Interval Management Evaluation); 2002/1

AVERT (Atorvastatin VErsus Revascularization Treatment); 1999/12

AVID (Antiarrhythmics Versus Implantable Defibrillators); 1999/5

BAATAF (Boston Area Anticoagulation Trial for Atrial Fibrillation); 1993/8

BARI (Bypass Angioplasty Revascularisation Investigation); 1997/5

BASIS (Basel Antiarrhythmic Study of Infarct Survival); 1998/1

Belfast Metoprolol Study; 1991/12

BENESTENT (Baloon-ExpaNdablE-STENT study); 1995/5

BHAT (Beta-blocker Heart Attack Trial); 1995/1

CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation); 1997/11

CAFA (Canadian Atrial Fibrillation Anticoagulation study); 1996/5–6

CAMIAT (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial); 1999/7–8

CAPARES (Coronary AngioPlasty Amlodipine REStenosis study); 2000/11–12

CAPE (Circadian Anti-ischemic Program in Europe); 2001/12

CARE (Cholesterol And Recurrent Events trial); 1998/11

CASH (Cardiac Arrest Study Hamburg); 1998/1

CASS (Coronary Artery Surgery Study); 1994/10

CAST (Cardiac Arrhytmia Suppression Trial); 1992/7

CAST (Chinese Acute Stroke Trial); 1998/3

CAVEAT (Coronary Angioplasty Versus Excisional Atherectomy Trial); 1993/12

CCS-1 (Chinese Cardiac Study); 1998/7–8

CELL (Cost-Effectiveness of Lipid Lowering); 1998/12

CHAOS (Cambridge Heart AntiOxidant Study); 1998/5

CHF-STAT (Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy); 1999/2

CIBIS (Cardiac Insufficiency BIsoprolol Study); 1998/7–8

CIBIS-II (Cardiac Insufficiency BIsoprolol Study II); 1999/6

CONSENSUS; 1992/1

CONSENSUS II. (COoperative New Scandinavian ENalapril SUrvival Study); 1993/7

Copenhagen-AFASAK (Copenhagen Atrie Flimmer ASpirin AntiKoagulation study); 1997/3

CRISP (Cholesterol Reduction In Seniors Program); 2001/6–7

DAAF (Digitalis in Acute Atrial Fibrillation); 2001/8–9

DART (Diet And Reinfarction Trial); 1995/4

DAVIT I. (DAnish Verapamil Infarction Trial I); 1994/3

DECREASE (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography) study; 2000/4

DEFIANT (Doppler flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy); 1993/2

DEFIANT-II. (Doppler flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy II.); 1997/10

DIG (The Digitalis Investigation Group); 1997/12

DIMT (Dutch Ibopamine Multicenter Trial); 1994/2

ECAT (European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study); 1993/10

ECSS (European Coronary Surgery Study); 1994/9

ELITE (Evaluation of Losartan In The Elderly); 1998/1

EMERAS (Estudio Multicentrico Estreptoquaninasa Republicas de America del Sud); 1998/2

EMIAT (European Myocardial Infarct Amiodarone Trial); 1998/7–8

EMIAT (European Myocardial Infarct Amiodarone Trial); 1999/9

ESPRIM (European Study of PRevention of Infarct with Molsidomine); 2000/1

ESVEM (Electrophysiologic Study Versus Electrocardiographic Monitoring); 1994/7

EVEREST’H (Evaluation of Verapamil for Efficacy, Safety and Tolerability in the management of Hypertension); 1992/11

FACET (Flosequinan-ACE inhibitor Trial); 1996/1

FISH (Finnish Isradipine Study in Hypertension); 1997/3

FLARE (FLuvastatin Angiographic REstenosis trial); 2000/1

GABI (German Angioplasty Bypass surgery Investigation); 1997/6

GAUS (German Activator Urokinase Study); 1996/11

GEMICA (Grupo de Estudio Multicéntrico del Infarto Con Amiodarone); 2001/4

GESICA (Grupo de Estudio de la Sobravida en la Insuficiencia Cardiaca en Argentina); 1999/5

GISSI I. (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto miocardico); 1994/8

GISSI-P (Group Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico – Prevenzione); 2000/10

HABIT (Hypertension And BPH Intervention Trial); 2000/6

HAEST (Heparin in Acute Embolic Stroke Trial); 2000/9

HALT (Hypertension And Lipid Trial); 1998/7–8

HAPPHY (Heart Attack Primary Prevention in HYpertension trial); 1994/2

HART (Heparin-Aspirin Reperfusion Trial); 1993/5

HEAP (Heparin in EArly Patency); 2000/11–12

Helsinki Heart Study; 1991/12

HOPE (Heart Outcomes Prevention Evaluation) study; 2000/5

HOT (Hypertension Optimal Treatment); 1999/9

INJECT (INternational Joint Efficacy Comparison of Thrombolytics); 1996/3–4

INSIGHT (International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment); 2001/5

INTACT (International Nifedipine Trial on Antiatherosclerotic Therapy); 1992/12

ISIS-1 (First International Study of Infarct Survival); 1992/8

ISIS-2 (Second International Study of Infarct Survival); 1992/8

ISIS-3 (Third International Study of Infarct Survival); 1992/10

ISIS-4 (Fourth International Study of Infarct Survival); 2000/2

LATE (Late Assessment of Thrombolytic Efficacy); 1995/12

LIFE (Losartan Intervention For Endpoint reduction in hypertension study); 2002/6–7

LIMIT-2 (Second Leicester Intravenous Magnesium Intervention Trial); 1999/1

LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease); 1999/1

LRT (Lovastatin Restenosis Trial); 1995/6

MADIT (Multicenter Automatic Defibrillator Implantation Trial); 1999/7–8

MAPHY (Metoprolol Atherosclerosis Prevention in HYpertension); 1992/7

MATTIS (Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting); 2000/2

MDPIT (Multicenter Diltiazem Post-Infarction Trial); 1996/11

MEHP (Metoprolol in Elderly Hypertension Patiens); 1996/12

MERCATOR (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis); 1996/12

MHFT (Munich mild Heart Failure Trial); 1997/1–2

MIDAS (Multicenter Isradipine Diuretic Atherosclerosis Study); 2001/5

MRFIT (Multiple Risk Factor Intervention Trial); 1992/3

4S (Scandinavian Simvastatin Survival Study); 1995/6

NORDIL (NORdic DILtiazem study); 2002/4

PASS (Practical Applicability of Saruplase Study); 1998/5

PEPI (Postmenopausal Estrogen/Progestin Interventions); 1999/3

PIAF (Pharmacological Intervention in Atrial Fibrillation); 2001/2

PPP (Primary Prevention Project); 2001/6–7

PRAISE (Prospective Randomized AmlodIpine Survival Evaluation); 1998/9

PRECISE (Prospective Randomized Evaluation of CarvedIlol on Symptoms and Exercise); 1998/11

PROMISE (Prospective RandOmized MIlrinone Survival Evaluation trial); 1997/4

RADIANCE [Randomized-Assessment of (the effect of) Digoxin on Inhibition of the AngiotensiN-Converting Enzyme study]; 1993/9

RaMI (Ravenna Myocardial Infarction trial); 2000/7–8

RED-LIP (REDuction in LIPid metabolism) study; 2000/5

REFLECT (Randomized Evaluation of FLosequian on ExCercise Tolerance study); 1996/2

REGRESS (REgression GRowth Evaluation Statin Study); 1997/4

REPAIR (REPerfusion in Acute Infarction, Rotterdam study); 1997/5

RITA-2 (The second Randomised Intervention Treatment of Angina); 1998/9

ROCKET (Regionally Organized Cardiac Key European Trial); 1992/12

SALT (Swedisch Aspirin Low-dose Trial); 1994/4

SAVE (Survival And Ventricular Enlargement trial); 1993/7

SHEP (Systolic Hypertension in the Elderly Program); 1992/9

SLIP (Study on Lipids with Isoptin Press); 1999/4

(S)MASH [(SWISS) Multicenter trial of Angioplasty for SHock]; 1999/10

SOLVD (Studies Of Left Ventricular Dysfunction); 1993/6

SPRINT (Secondary Prevention Reinfarction Israeli Nifedipine); 1995/10

STIMS (Swedish TiclopIdine Multicentre Study); 1993/10

STRESS (STent REStenosis Study); 1995/4

Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure; 1996/1

SWIFT (Should We Intervence Following Thrombolysis); 1998/10

SWORD (Survival With ORal D-sotalol); 1998/10

TACT (Ticlopidine Angioplastie Coronaire Transluminale); 2002/3

TASS (Ticlopidine Aspirin Stroke Study); 1993. október

TEMS (Trimetazidine European Multicenter Study); 2001/12

TIBBS (Total Ischemic Burden Bisoprolol Study); 1999/10

TIMI I. (Thrombolysis In Myocardial Infarction phase I.); 1994/8

TIMI II. (Thrombolysis In Myocardial Infarction phase II.); 1994/10

TOMHS (Treatment Of Mild Hypertension Study); 2001/12

TONE (Trial Of Nonpharmacologic interventions in the Elderly); 2001/4

TOPS (Treatment Of Post-thrombolytic Stenoses); 1997/9

Transmyocardial revascularization with CO₂, laser in patients with refractory angina pectoris. Clinical results from the Norwegian Randomized Trial; 2001/3

UK-TIA (United Kingdom Transient Ischaemic Attack study); 1993/6

USIM (Urochinasi per via Sistemica nell’Infarto Miocardico); 1998/7–8

V-HEFT (Vasodilator-HEart Failure Trial I-II).; 1993/1

WARIS (WArfarin ReInfarction Study); 1997/1–2

Xamoterol in severe heart failure; 1993/2